NervGen Pharma Statistics
Total Valuation
NervGen Pharma has a market cap or net worth of $233.65 million. The enterprise value is $221.78 million.
| Market Cap | 233.65M |
| Enterprise Value | 221.78M |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NervGen Pharma has 106.20 million shares outstanding. The number of shares has increased by 6.72% in one year.
| Current Share Class | 106.20M |
| Shares Outstanding | 106.20M |
| Shares Change (YoY) | +6.72% |
| Shares Change (QoQ) | +8.69% |
| Owned by Insiders (%) | 1.91% |
| Owned by Institutions (%) | 4.24% |
| Float | 94.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 44.28 |
| P/TBV Ratio | 63.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.34
| Current Ratio | 1.34 |
| Quick Ratio | 1.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -1,207.46% and return on invested capital (ROIC) is -473.69%.
| Return on Equity (ROE) | -1,207.46% |
| Return on Assets (ROA) | -90.75% |
| Return on Invested Capital (ROIC) | -473.69% |
| Return on Capital Employed (ROCE) | -479.57% |
| Weighted Average Cost of Capital (WACC) | 8.05% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.00M |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.25% in the last 52 weeks. The beta is 0.69, so NervGen Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.69 |
| 52-Week Price Change | -13.25% |
| 50-Day Moving Average | 3.15 |
| 200-Day Moving Average | 3.60 |
| Relative Strength Index (RSI) | 42.68 |
| Average Volume (20 Days) | 1,783,590 |
Short Selling Information
The latest short interest is 3.09 million, so 2.91% of the outstanding shares have been sold short.
| Short Interest | 3.09M |
| Short Previous Month | 1.56M |
| Short % of Shares Out | 2.91% |
| Short % of Float | 3.28% |
| Short Ratio (days to cover) | 2.71 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -19.04M |
| Pretax Income | -29.98M |
| Net Income | -29.98M |
| EBITDA | -19.00M |
| EBIT | -19.04M |
| Earnings Per Share (EPS) | -$0.40 |
Balance Sheet
The company has $11.86 million in cash and n/a in debt, with a net cash position of $11.86 million or $0.11 per share.
| Cash & Cash Equivalents | 11.86M |
| Total Debt | n/a |
| Net Cash | 11.86M |
| Net Cash Per Share | $0.11 |
| Equity (Book Value) | 3.97M |
| Book Value Per Share | 0.05 |
| Working Capital | 3.69M |
Cash Flow
| Operating Cash Flow | -16.89M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 39,455 |
| Net Borrowing | -59,474 |
| Free Cash Flow | -16.67M |
| FCF Per Share | -$0.16 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NervGen Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.72% |
| Shareholder Yield | -6.72% |
| Earnings Yield | -12.83% |
| FCF Yield | -7.14% |
Analyst Forecast
The average price target for NervGen Pharma is $11.21, which is 409.55% higher than the current price. The consensus rating is "Buy".
| Price Target | $11.21 |
| Price Target Difference | 409.55% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |